High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group (Q36115868)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group (English)

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

1 reference

based on heuristic

inferred from title

author name string

Nielsen OS

1

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Dombernowsky P

2

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Mouridsen H

3

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Crowther D

4

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Verweij J

5

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Buesa J

6

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Steward W

7

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Daugaard S

8

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

van Glabbeke M

9

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Kirkpatrick A

10

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Tursz T

11

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

language of work or name

0 references

publication date

1 December 1998

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

British Journal of Cancer

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

78

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

12

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

1634-1639

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

The present state of the art in chemotherapy for soft tissue sarcomas in adults: the EORTC point of view

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063236

2 October 2017

Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063236

2 October 2017

The management of adult soft tissue sarcomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063236

2 October 2017

Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063236

2 October 2017

Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063236

2 October 2017

Regaud Lecture, Granada 1994. Tumors of the connective and supporting tissues

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063236

2 October 2017

The importance of dose intensity in chemotherapy of metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063236

2 October 2017

Cyvadic in advanced soft tissue sarcoma: A randomized study comparing two schedules: A study of the EORTC soft tissue and bone sarcoma group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063236

2 October 2017

Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063236

2 October 2017

Quality control of validity of data collected in clinical trials. EORTC Study Group on Data Management (SGDM).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063236

2 October 2017

Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063236

2 October 2017

Carminomycin vs adriamycin in advanced soft tissue sarcomas: an EORTC randomised phase II study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063236

23 September 2018

High-dose epirubicin-cisplatin chemotherapy for advanced soft tissue sarcoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063236

23 September 2018

Doxorubicin in relapsed soft tissue sarcoma: justification of phase II evaluation of new drugs in this disease. An EORTC Soft Tissue and Bone Sarcoma Group Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/9862576

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II trial of mitoxantrone in advanced sarcomas: a Southwest Oncology Group study

1 reference

https://pubmed.ncbi.nlm.nih.gov/9862576

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adriamycin versus epirubicin in advanced soft tissue sarcomas. A randomized phase II/phase III study of the EORTC Soft Tissue and Bone Sarcoma Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/9862576

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of epirubicin in advanced soft tissue sarcoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/9862576

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/BJC.1998.735

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36115868&oldid=2198222415"